These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 23311918)
1. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry. Purkait S; Jha P; Sharma MC; Suri V; Sharma M; Kale SS; Sarkar C Neuropathology; 2013 Aug; 33(4):405-12. PubMed ID: 23311918 [TBL] [Abstract][Full Text] [Related]
2. Pediatric glioblastomas: a histopathological and molecular genetic study. Suri V; Das P; Pathak P; Jain A; Sharma MC; Borkar SA; Suri A; Gupta D; Sarkar C Neuro Oncol; 2009 Jun; 11(3):274-80. PubMed ID: 18981259 [TBL] [Abstract][Full Text] [Related]
3. Genetic analyses for predictors of radiation response in glioblastoma. Shih HA; Betensky RA; Dorfman MV; Louis DN; Loeffler JS; Batchelor TT Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):704-10. PubMed ID: 15978739 [TBL] [Abstract][Full Text] [Related]
4. Molecular genetic analysis of giant cell glioblastomas. Meyer-Puttlitz B; Hayashi Y; Waha A; Rollbrocker B; Boström J; Wiestler OD; Louis DN; Reifenberger G; von Deimling A Am J Pathol; 1997 Sep; 151(3):853-7. PubMed ID: 9284834 [TBL] [Abstract][Full Text] [Related]
5. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. Burns KL; Ueki K; Jhung SL; Koh J; Louis DN J Neuropathol Exp Neurol; 1998 Feb; 57(2):122-30. PubMed ID: 9600204 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas. Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763 [TBL] [Abstract][Full Text] [Related]
8. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors]. Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323 [No Abstract] [Full Text] [Related]
9. EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index. Purkait S; Sharma V; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Sarkar C Neuropathology; 2015 Oct; 35(5):421-31. PubMed ID: 26096306 [TBL] [Abstract][Full Text] [Related]
10. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Nielsen GP; Burns KL; Rosenberg AE; Louis DN Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476 [TBL] [Abstract][Full Text] [Related]
11. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857 [TBL] [Abstract][Full Text] [Related]
12. The rate of homozygous CDKN2A/p16 deletions in glioma cell lines and in primary tumors. Hartmann C; Kluwe L; Lücke M; Westphal M Int J Oncol; 1999 Nov; 15(5):975-82. PubMed ID: 10536182 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568 [TBL] [Abstract][Full Text] [Related]
14. p14ARF deletion and methylation in genetic pathways to glioblastomas. Nakamura M; Watanabe T; Klangby U; Asker C; Wiman K; Yonekawa Y; Kleihues P; Ohgaki H Brain Pathol; 2001 Apr; 11(2):159-68. PubMed ID: 11303791 [TBL] [Abstract][Full Text] [Related]
15. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Jha P; Suri V; Singh G; Jha P; Purkait S; Pathak P; Sharma V; Sharma MC; Suri A; Gupta D; Mahapatra AK; Sarkar C Diagn Mol Pathol; 2011 Dec; 20(4):225-32. PubMed ID: 22089350 [TBL] [Abstract][Full Text] [Related]
16. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755 [TBL] [Abstract][Full Text] [Related]
17. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden). de vos tot Nederveen Cappel WH; Offerhaus GJ; van Puijenbroek M; Caspers E; Gruis NA; De Snoo FA; Lamers CB; Griffioen G; Bergman W; Vasen HF; Morreau H Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3598-605. PubMed ID: 14506146 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. Kawaguchi K; Oda Y; Saito T; Yamamoto H; Tamiya S; Takahira T; Miyajima K; Iwamoto Y; Tsuneyoshi M J Pathol; 2003 Nov; 201(3):487-95. PubMed ID: 14595762 [TBL] [Abstract][Full Text] [Related]
19. p16INK4A (CDKN2A) gene deletion is a frequent genetic event in synovial sarcomas. Subramaniam MM; Noguera R; Piqueras M; Navarro S; López-Guerrero JA; Llombart-Bosch A Am J Clin Pathol; 2006 Dec; 126(6):866-74. PubMed ID: 17074682 [TBL] [Abstract][Full Text] [Related]
20. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features. Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]